Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts

被引：36

作者：

Okabe, Teruo ^{[1
]}

Lindsay, Joseph ^{[1
]}

Buch, Ashesh N. ^{[1
]}

Steinberg, Daniel H. ^{[1
]}

Roy, Probal ^{[1
]}

Slottow, Tina L. Pinto ^{[1
]}

Smith, Kimberly ^{[1
]}

Torguson, Rebecca ^{[1
]}

Xue, Zhenyi ^{[1
]}

Satler, Lowell F. ^{[1
]}

Kent, Kenneth M. ^{[1
]}

Pichard, Augusto D. ^{[1
]}

Weissman, Neil J. ^{[1
]}

Waksman, Ron ^{[1
]}

机构：

[1] Washington Hosp Ctr, Cardiovasc Res Inst, Washington, DC 20010 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2008年 / 102卷 / 05期

关键词：

D O I：

10.1016/j.amjcard.2008.04.041

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Conflicting data exist regarding an advantage of drug-eluting stents (DES) over bare metal stents (BMS) in catheter-based treatment of saphenous vein graft (SVG) stenoses. This study was undertaken to compare the efficacy of these modalities in that lesion subset. The DES group consisted of 138 cases with 183 lesions (sirolimus-eluting stents, n = 117; paclitaxel-eluting stents, n = 66) and the BMS group consisted of 344 cases with 478 lesions that were followed to 1 year. We examined a composite end point that comprised death, Q-wave myocardial infarction, and target lesion revascularization. More BMS were deployed per patient (p < 0.001) and the diameters of BMS deployed was significantly greater (p < 0.001). Peak postprocedure values of creatine kinase-MB (p = 0.003) and troponin I (p = 0.05) were higher in BMS. At 1 year there was no significant superiority of DES over BMS with regard to hard end points (death and Q-wave myocardial infarction). In conclusion, this study indicates that both DES and BMS for SVG disease provide acceptably safe and efficacious results, but unlike the case in native coronary arteries, DES use does not reduce the frequency of the need for repeat revascularization. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：530 / 534

页数：5

共 20 条

[1] Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting [J].

Bhargava, B ;

Kornowski, R ;

Mehran, R ;

Kent, KM ;

Hong, MK ;

Lansky, AJ ;

Waksman, R ;

Pichard, AD ;

Satler, LF ;

Leon, MB .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) :389-397

[2] Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention [J].

Chu, WW ;

Rha, SW ;

Kuchulakanti, PK ;

Cheneau, E ;

Torguson, R ;

Pinnow, E ;

Alexieva-Fournadjiev, J ;

Pichard, AD ;

Satler, LF ;

Kent, KM ;

Lindsay, J ;

Waksman, R .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (01) :34-37

[3] Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions [J].

Colombo, A ;

Drzewiecki, J ;

Banning, A ;

Grube, E ;

Hauptmann, K ;

Silber, S ;

Dudek, D ;

Fort, S ;

Schiele, F ;

Zmudka, K ;

Guagliumi, G ;

Russell, ME .

CIRCULATION, 2003, 108 (07) :788-794

[4] Long-term clinical outcome after stent implantation in saphenous vein grafts [J].

deJaegere, PP ;

vanDomburg, RT ;

deFeyter, PJ ;

Ruygrok, PN ;

vanderGiessen, WJ ;

vandenBrand, MJ ;

Serruys, PW .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (01) :89-96

[5] Treatment of saphenous vein graft lesions with drug-eluting stents - Immediate and midterm outcome [J].

Ge, L ;

Iakovou, I ;

Sangiorgi, GM ;

Chieffo, A ;

Melzi, G ;

Cosgrave, J ;

Montorfano, M ;

Michev, I ;

Airoldi, F ;

Carlino, M ;

Corvaja, N ;

Colombo, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (07) :989-994

[6] Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions [J].

Grube, E ;

Silber, S ;

Hauptmann, KE ;

Mueller, R ;

Buellesfeld, L ;

Gerckens, U ;

Russell, ME .

CIRCULATION, 2003, 107 (01) :38-42

[7] Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality [J].

Hong, MK ;

Mehran, R ;

Dangas, G ;

Mintz, GS ;

Lansky, AJ ;

Pichard, AD ;

Kent, KM ;

Satler, LF ;

Stone, GW ;

Leon, MB .

CIRCULATION, 1999, 100 (24) :2400-2405

[8] Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries - A serial volumetric intravascular ultrasound analysis from the ASian paclitaxel-eluting stent clinical trial (ASPECT) [J].

Hong, MK ;

Mintz, GS ;

Lee, CW ;

Song, JM ;

Han, KH ;

Kang, DH ;

Song, JK ;

Kim, JJ ;

Weissman, NJ ;

Fearnot, NE ;

Park, SW ;

Park, SJ .

CIRCULATION, 2003, 107 (04) :517-520

[9] Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts [J].

Keeley, EC ;

Velez, CA ;

O'Neill, WW ;

Safian, RD .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (03) :659-665

[10] Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis [J].

Mishra, Sundeep ;

Wolfram, Roswitha M. ;

Torguson, Rebecca ;

Chu, William W. ;

Xue, Zhenyi ;

Gevorkian, Natalie ;

Donekal, Sirisha ;

Chan, Rosanna ;

Pichard, Augusto D. ;

Satler, Lowell F. ;

Kent, Kenneth M. ;

Waksman, Ron .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (09) :1303-1307

← 1 2 →